Generate Biomedicines, Inc.
GENB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002100782
In the last 90 days, Generate Biomedicines, Inc. insiders filed 0 open-market purchases and 1 sale; 86 institutions reported holding it in 13F filings for Q2 2026, worth $1.69B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $16.0K in total
- 1
- 13F holdersQ2 2026, +29 vs. previous quarter
- 86
- 13F valueReported value at the end of Q2 2026
- $1.69B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding GENB, Q2 2026
1 superinvestor reports holding Generate Biomedicines, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
0.1%
Generate Biomedicines, Inc.'s share of the portfolio
- Shares
- 1,284,617
- Value
- $21.7M
Latest insider trades
Open-market purchases and sales by Generate Biomedicines, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)4:05 PM ET | Sep 1 | 2 days | Arnold FrancesDirector | SSale | −1.00K | $16.00 | −$16.0K | −0.4%231.5K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Nally MichaelChief Executive Officer | PPurchase | +20.0K | $12.00 | +$240.0K | +3.6%572.7K after | |
| Mar 2, 2026 (view filing)5:52 PM ET | Mar 2 | Same day | Afeyan Noubar and 7 othersDirector, 10% Owner | PPurchase | +4.69M | $16.00 | +$75.0M | New position1.56M after | 3 lotsDuplicate filing |
| Mar 2, 2026 (view filing)5:42 PM ET | Mar 2 | Same day | Afeyan Noubar and 6 othersDirector, 10% Owner | PPurchase | +4.69M | $16.00 | +$75.0M | New position1.56M after | 3 lots |
| Mar 2, 2026 (view filing) | Mar 2 | Same day | Grous BethChief People Officer | PPurchase | +300 | $16.00 | +$4.80K | New position300 after | |
| Mar 2, 2026 (view filing) | Mar 2 | Same day | Silvers JasonPresident & CFO | PPurchase | +2.00K | $16.00 | +$32.0K | New position1.00K after | 3 lots |
| Mar 2, 2026 (view filing) | Mar 2 | Same day | Mendillo Jane LDirector | PPurchase | +1.50K | $16.00 | +$24.0K | New position1.50K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Generate Biomedicines, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 62,673,117 | $1.06B | 68.66% | 00.0% | Unchanged |
| FMR LLC | 5,221,599 | $88.1M | 0.00% | +1,004,075+23.8% | Added |
| Capital World Investors | 4,215,632 | $71.1M | 0.01% | +211,483+5.3% | Added |
| Braidwell LP | 3,283,844 | $55.4M | 2.05% | −309,155−8.6% | Reduced |
| Price T Rowe Associates Inc | 2,156,627 | $36.4M | 0.00% | +46,994+2.2% | Added |
| Norges Bank | 2,094,616 | $35.3M | 0.00% | +2,094,616 | New |
| ARCH Venture Management, LLC | 1,944,426 | $32.8M | 2.98% | 00.0% | Unchanged |
| HarbourVest Partners LLC | 1,722,210 | $29.1M | 17.09% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,659,966 | $28.0M | 0.00% | +1,659,966 | New |
| Baker Bros. Advisors LP | 1,423,602 | $24.0M | 0.12% | 00.0% | Unchanged |